VolitionRx Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. announced that it is preparing a reimbursement submission for its Nu.Q Cancer assays to government agencies in France. The submission will be actively supported by Hospices Civils de Lyon, France's second-largest university hospital system, and will run in parallel with the previously announced clinical certification process at HCL. HCL researchers said the Nu.Q Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France following completion of the reimbursement and certification processes.

Data generated through collaboration with Volition indicate that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis can provide information related to survival and disease progression. This approach may also help identify patients who could benefit from curative care. Volition said the reimbursement submission is expected to be filed under France's Innovative Procedures Outside the Nomenclature framework, which allows early reimbursement support for innovative medical procedures. The company noted that reimbursement would represent a major milestone toward routine clinical use of Nu.Q Cancer assays in France and support broader commercialization and potential licensing discussions in other markets.

The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. For further information, visit the company's website at https://www.Volition.com. The press release was distributed through BioMedWire, a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via https://www.InvestorWire.com to efficiently and effectively reach a myriad of target markets, demographics and diverse industries.

BioMedWire also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.